BioNTech ADR had its Relative Strength (RS) Rating upgraded from 80 to 84 Wednesday.
This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
BioNTech ADR is trying to complete a consolidation with a 131.49 entry. See if it can break out in heavy volume.
BioNTech ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 29%. Revenue rose from -25% to 46%.
The company earns the No. 98 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
